TITLE

Value-based drug system proposed in UK

AUTHOR(S)
Collier, Roger
PUB. DATE
November 2010
SOURCE
CMAJ: Canadian Medical Association Journal;11/23/2010, Vol. 182 Issue 17, pE773
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the adoption of a value-based drug pricing scheme in Great Britain. It mentions that the country implements a price-taker system wherein governments determine whether or not to cover the pricing system set by drug companies under public finance based on cost-effectiveness. It says that the proposed pricing scheme may face various challenges such as quantifying therapeutic benefits and making more bureaucratic barriers for drug companies affecting economic development.
ACCESSION #
55704784

 

Related Articles

  • Policy & Price. Gopal, Kevin // Pharmaceutical Executive;Aug99, Vol. 19 Issue 8, p30 

    Focuses on the renegotiation of the Pharmaceutical Price Regulation Scheme (PPRS) between the British government and the pharmaceutical industry. Price reduction of branded medicines; Measures that offset the price reduction in the PPRS; How the PPRS gave the government an economic opportunity.

  • Government pushes for 2.5% cut in drug prices.  // BMJ: British Medical Journal (International Edition);8/21/93, Vol. 307 Issue 6902, p464 

    Reports the pharmaceutical price regulation scheme of drugs in Great Britain. Aims of drug price reduction; Factors contributing to excess profits in the pharmaceutical industry; Recommendation on the improvement of prescribing practices among general practitioners.

  • Huge Sellers' Herald Changes in Japan Drug Pricing. Macarthur, Donald // Pharmaceutical Executive Global Digest;Oct2016, Vol. 36 Issue 10, p40 

    The article discusses the increase of prescription drug sales in Japan in 2015, the introduction of mandatory cost-effectiveness standards and the revision of pricing rules of drugs targeting those marketed drugs considered as huge sellers including Opdivo and Repatha.

  • Report from: Philippines. Wan, Jane // Pharmaceutical Technology;Nov2009, Vol. 33 Issue 11, p18 

    The article presents the pharmaceutical market report for the Philippines. It states that the Philippine government has imposed a heartening 50 percent price cut on certain drugs for hypertension, diabetes, and amoebiasis with mandatory compliance to the Maximum Drug Retail Price (MDRP) system....

  • PhRMA wins! Federal judge blocks Maine price control law, but drug program proceeds.  // Medical Marketing & Media;Dec2000, Vol. 35 Issue 12, p20 

    Reports on a Maine federal court's issuance of a preliminary injunction sought by the Pharmaceutical Research and Manufacturers of America against the state's drug price control policy. Provisions of the price control law; Continuous implementation of other parts of the law not affected by the...

  • The Great Pharmacy Rip-off. Ragg, Mark // Bulletin with Newsweek;12/08/98, Vol. 117 Issue 6152, p26 

    Presents information on the deal between the Australian government under Hawke and the Pharmacy Guild over the price charged to the public for prescription drugs. The government and the pharmacists agreeing that the public should pay more; Secrecy about the agreement; Details on the various...

  • BIG PHARMA'S DRUG PROBLEM. Surowiecki, James // New Yorker;10/16/2000-10/23/2000, Vol. 76 Issue 31, p98 

    Focuses on the pharmaceutical industry of the United States and the role of the regulatory system in the high prices of drugs. Skill of the drug industry in protecting its patents; Formula for lowering drug prices; Reason for the existence of the patent system.

  • Regulating the pharmaceutical industry. Maynard, Alan; Bloor, Karen // BMJ: British Medical Journal (International Edition);07/26/97, Vol. 315 Issue 7102, p200 

    Editorial. Discusses a voluntary scheme intended to regulate pricing policies of drugs in Great Britain. Negotiation of target profit sales from sales of drugs to the National Health Service; Evidence of the scheme's success; Conflict between attempts to control NHS expenditure and subsidy of...

  • Maine's Rx Drug Pricing Measure Is Uncertain to Pass.  // Chemical Market Reporter;03/19/2001, Vol. 259 Issue 12, p28 

    Examines the legal problem on the enactment of the proposed state legislation in Maine regarding the control of prescription drug prices. Terms of the proposed legislation; Claims of the Pharmaceutical Research and Manufacturers of America that the law is unconstitutional; Impact of the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics